NCT03217643 - CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

November 21, 2022

Study Completion Date

May 15, 2023

Conditions

Enteropathy Associated T-cell Lymphoma

Interventions

DRUG

Brentuximab Vedotin

The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.

Trial Locations (1)

Unknown

Hopital Necker - Enfants malades, Paris